Yang Bangkun, Zhang Ji-Chun, Han Mei, Yao Wei, Yang Chun, Ren Qian, Ma Min, Chen Qian-Xue, Hashimoto Kenji
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan.
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Psychopharmacology (Berl). 2016 Oct;233(19-20):3647-57. doi: 10.1007/s00213-016-4399-2. Epub 2016 Aug 4.
The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression.
We compared the rapid and sustained antidepressant effects of R-ketamine and rapastinel in the social defeat stress model.
In the tail suspension and forced swimming tests, R-ketamine (10 mg/kg, intraperitoneal (i.p.)) or rapastinel (10 mg/kg, i.p.) significantly attenuated the increased immobility time in the susceptible mice, compared with the vehicle-treated group. In the sucrose preference test, both compounds significantly enhanced the reduced preference in susceptible mice 2, 4, or 7 days after a single injection. All mice were sacrificed 8 days after a single injection. Western blot analyses showed that R-ketamine, but not rapastinel, significantly attenuated the reduced brain-derived neurotrophic factor (BDNF)-TrkB signaling, postsynaptic density protein 95 (PSD-95), and GluA1 (a subtype of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor) in the prefrontal cortex, dentate gyrus, and CA3 of the hippocampus in the susceptible mice. In contrast, both compounds had no effect against the increased BDNF-TrkB signaling, PSD-95, and GluA1 seen in the nucleus accumbens of susceptible mice. Moreover, sustained antidepressant effect of R-ketamine (3 mg/kg, intravenous (i.v.)), but not rapastinel (3 mg/kg, i.v.), was detected 7 days after a single dose.
These results highlight R-ketamine as a longer lasting antidepressant compared with rapastinel in social defeat stress model. It is likely that synaptogenesis including BDNF-TrkB signaling in the prefrontal cortex (PFC) and hippocampus may be required for the mechanisms promoting this sustained antidepressant effect.
N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,包括R-氯胺酮和瑞帕斯汀(原名GLYX-13),在抑郁症动物模型中显示出快速的抗抑郁作用。
我们比较了R-氯胺酮和瑞帕斯汀在社会挫败应激模型中的快速和持续抗抑郁作用。
在悬尾试验和强迫游泳试验中,与溶剂处理组相比,R-氯胺酮(10mg/kg,腹腔注射(i.p.))或瑞帕斯汀(10mg/kg,i.p.)显著缩短了易感小鼠的不动时间增加。在蔗糖偏好试验中,单次注射后2、4或7天内,两种化合物均显著提高了易感小鼠降低的偏好性。单次注射后8天处死所有小鼠。蛋白质免疫印迹分析表明,R-氯胺酮而非瑞帕斯汀显著减弱了易感小鼠前额叶皮质、齿状回和海马CA3区中脑源性神经营养因子(BDNF)-TrkB信号通路、突触后致密蛋白95(PSD-95)和GluA1(α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的一种亚型)的降低。相反,两种化合物对易感小鼠伏隔核中BDNF-TrkB信号通路、PSD-95和GluA1的增加均无作用。此外,单次给药7天后检测到R-氯胺酮(3mg/kg,静脉注射(i.v.))有持续抗抑郁作用,而瑞帕斯汀(3mg/kg,i.v.)则没有。
这些结果表明,在社会挫败应激模型中,与瑞帕斯汀相比,R-氯胺酮是一种作用更持久的抗抑郁药。促进这种持续抗抑郁作用的机制可能需要前额叶皮质(PFC)和海马中包括BDNF-TrkB信号通路在内的突触形成。